SCHEMBL5147602

SCHEMBL5147602

NC(=O)c1nnsc1Nc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ILK Q13418 3/20 1.00
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
JAK2 O60674 3/20 0.46
MAPT P10636 7/20 0.44
LMNA P02545 4/20 0.44
USP2 O75604 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TNIK Q9UKE5 1/20 0.43
PIP5K1C O60331 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GAA P10253 2/20 0.42
GFER P55789 1/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
TP53 P04637 2/20 0.41
POLB P06746 1/20 0.41
LRRK2 Q5S007 1/20 0.40
JAK3 P52333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147923 0.87 ILK (0.77) ILKMEN1KMT2AJAK2MAPT
SCHEMBL5147927 0.87 ILK (0.77) ILKMEN1KMT2AJAK2MAPT
SCHEMBL5146269 0.87 ILK (0.77) ILKMEN1KMT2AMAPTLMNA
SCHEMBL5147557 0.85 ILK (0.74) ILKMEN1KMT2AJAK2MAPT
SCHEMBL5146289 0.84 ILK (0.73) ILKMEN1KMT2AMAPTLMNA
SCHEMBL5149415 0.84 ILK (0.73) ILKMEN1KMT2AMAPTLMNA
SCHEMBL5146319 0.84 ILK (0.73) ILKMEN1KMT2AJAK2MAPT
SCHEMBL5147677 0.82 ILK (0.68) ILKMEN1KMT2ASMN1; SMN2
SCHEMBL5146331 0.82 ILK (0.69) ILKMEN1KMT2AMAPTTNIK
SCHEMBL5147724 0.81 ILK (0.68) ILKMEN1KMT2AJAK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288556-B2 Antiproliferative 1,2,3-thiadiazole compounds QLT INC. (CA) 2007-10-30 US disclosed
US-7022702-B2 Antiproliferative 1,2,3-thiadiazole compounds QLT INC. (CA) 2006-04-04 US disclosed
US-20060009500-A1 Antiproliferative 1,2,3-thiadiazole compounds QLT INC. (CA) 2006-01-12 US disclosed
US-20030096848-A1 Antiproliferative 1,2,3-thiadiazole compounds DERMIRA (CANADA), INC. 2003-05-22 US disclosed
US-6420400-B1 ANTITUMOR, ANGIOGENESIS INHIBITOR, CONTROLLING CELL PROLIFERATION KINETEK PHARMACEUTICALS, INC. (CA) 2002-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096848-A1 Antiproliferative 1,2,3-thiadiazole compounds CCNA1, CCND1, CCND3 ILK 1286/4885MEN1 2585/4885KMT2A 3558/4885
US-20060009500-A1 Antiproliferative 1,2,3-thiadiazole compounds CCNA1, CCND3, ACIN1 ILK 2862/4885MEN1 1548/4885KMT2A 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.